TY - JOUR
T1 - Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months
T2 - Final comparative results of the EVIDENCE trial
AU - Panitch, Hillel
AU - Goodin, Douglas
AU - Francis, Gordon
AU - Chang, Peter
AU - Coyle, Patricia
AU - O'Connor, Paul
AU - Li, David
AU - Weinshenker, Brian
PY - 2005/12/15
Y1 - 2005/12/15
N2 - The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.
AB - The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.
KW - Comparative study
KW - Interferon beta
KW - Magnetic resonance imaging (MRI)
KW - Multiple sclerosis (MS)
KW - Neutralizing antibodies
UR - http://www.scopus.com/inward/record.url?scp=27744516986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744516986&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2005.08.003
DO - 10.1016/j.jns.2005.08.003
M3 - Article
C2 - 16169561
AN - SCOPUS:27744516986
SN - 0022-510X
VL - 239
SP - 67
EP - 74
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
IS - 1
ER -